Loading…
← CockpitCompetitor Analysis › ADPT Adaptive Biotechnologies Corp.Open in the cockpit ↗

Adaptive Biotechnologies Corp.ADPTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Runs immune-sequencing technology (clonoSEQ, T-Detect) to measure disease at the molecular level for diagnostics and drug discovery.

Momentum leader 97
Mkt cap
$4.61B
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$64.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-27.3 pp
WACC 15.1%
Hurdle
n/a
no reverse DCF
Next earnings
90 days
16 Feb 2027
Close · USD$28.46
1D-0.1%
1W-4.9%
1M+16.5%
3M+11.9%
6M+103.9%
YTD+75.2%
1Y+107.6%
ATR %6.1%
Beta1.48
52w lowhigh11.6% off high

What Adaptive Biotechnologies does

Runs immune-sequencing technology (clonoSEQ, T-Detect) to measure disease at the molecular level for diagnostics and drug discovery.

Bills per test: clonoSEQ checks for leftover cancer cells in blood cancers, and Medicare and other insurers pay a set fee, so test volume and coverage decisions matter most. A second line sells sequencing services and drug-discovery work to pharmaceutical partners, paid by fees and milestones.

Products and services

  • clonoSEQ (MRD testing for blood cancers)
  • Immune medicine/drug discovery partnerships
  • T-Detect immune diagnostics

Customers

  • Oncologists/hospitals
  • Pharma partners (drug discovery collaborations)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Immune-repertoire sequencing platform

What could go right

  • clonoSEQ reimbursement and adoption growth
  • Pharma partnership milestone payments

What could go wrong

  • Reimbursement uncertainty
  • Cash burn ahead of profitability

Moat: narrow (IP / patents, data, installed base). Proprietary immune-sequencing database and an FDA-cleared MRD test create a data moat and switching costs.

Headquarters: Seattle, Washington, US · Founded: 2009 · Employees: 624

Named competitors

Adaptive Biotechnologies at a glance

Size Adaptive Biotechnologies (ADPT) is a United States Health Care company (Biotechnology) with a market value of $4.61B, the 1235th largest of 3,085 United States companies the cockpit tracks. Shares closed at $28.46 on 18 Nov 2026.

Performance Over six months the shares gained 103.9%, against -0.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 17.9% over the last twelve months (peer median -1.2%); the operating margin is -15.6% (peer median -35.0%).

Valuation It trades at 15.8× enterprise value to sales against a peer median of 12.7× (7th most expensive of 16).

Capital Return on invested capital runs 27.3 points below its cost of capital (15.1% WACC).

Short interest Short interest is 7.1% of the free float (30 Oct 2026).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026ADPT 205Peer median 101
Six months, rebased to 100: Adaptive Biotechnologies against the median of its 20 peers (local-currency closes).

Adaptive Biotechnologies financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$298M$277M$179M$170M$185M
Revenue growth—+55%+5%-8%—
Gross profit$213M$194M$96.6M$72.5M$106M
EBITDA-$31.1M-$39.3M-$134M-$179M-$170M
Net income-$70.5M-$59.5M-$159M-$225M-$200M
Free cash flow-$8.82M-$48.9M-$98.9M-$167M-$200M
Capital expenditure$4.54M$2.96M$3.66M$10.7M$16.3M
Total debt$409M$210M$223M$229M$233M

Quarterly statements and history in the cockpit →

Adaptive Biotechnologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%002252EWTX000661DNTH3347COGT15306033923001226696CRSPANTHEMCAITNGX6127RLAYSRRKABCLIRONARWRADPT6-month return →1-month return →
Up and to the right = strong over both horizons. Adaptive Biotechnologies is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%0×500×1,000×1,500×002252000661DNTH33471530603392CRSPANTHEMCAIRLAYABCLARWRADPTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Adaptive Biotechnologies is the large dot.

Adaptive Biotechnologies competitors and peer comparison

Head to head with its named competitors (ADPT vs NTRA vs GH vs NEO)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Adaptive Biotechnologies ADPT$4.61B+104%+18%-16%15.8×n/a
Natera NTRA$42.0B+41%+37%-9%14.1×n/a
Guardant Health GH$19.6B+26%+42%-39%15.9×n/a
NeoGenomics NEO$1.98B+72%+11%-6%2.9×n/a
Personalis PSNL$1.62B+88%+17%-157%18.2×n/a
Tempus AI TEM$11.6B+39%+37%-18%8.2×n/a

How Adaptive Biotechnologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Adaptive Biotechnologies against its 20 peers (data as of 18 Nov 2026)
MeasureADPTPeer medianRank in peer set
1-month return+16.5%-7.7%2nd highest of 21
6-month return+103.9%-0.3%3rd highest of 21
Distance from 52-week high-11.6%-33.1%2nd highest of 21
Revenue growth (TTM)+17.9%-1.2%6th highest of 16
Operating margin-15.6%-35.0%8th highest of 16
EV / Sales15.8×12.7×7th most expensive of 16
ROIC minus cost of capital-27.3 pp-9.8 pp4th lowest of 13

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%10%4.8×25.4%+15.6%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%12.4×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a

Questions

Who are Adaptive Biotechnologies's main competitors?
Named competitors: Natera (NTRA), Guardant Health (GH), Exact Sciences (private or unlisted), NeoGenomics (NEO), Personalis (PSNL), Tempus AI (TEM). The cockpit's measured peer set (industry) also includes Shanghai RAAS Blood Products (002252.SZ), Edgewise Therapeutics (EWTX), Changchun High-Tech Industry (Group) (000661.SZ), Dianthus Therapeutics (DNTH), Hangzhou Tigermed Consulting (3347.HK), Cogent Biosciences (COGT).
Is Adaptive Biotechnologies expensive compared with its peers?
On ev / sales it trades at 15.8× against a peer median of 12.7×, 7th most expensive of 16 in its peer set.
How has Adaptive Biotechnologies stock performed?
Over six months to 18 Nov 2026 the shares returned +103.9% against -0.3% for the median peer; over one year +107.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.